[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368972-105":59,"doc-detail-368972-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tissue-microarray-based-digital-spatial-profiling-of-benign-breast-lobules-and-breast-cancers-feasibility-biological-coherence-and-cross-platform-benchmarks","Tissue Microarray-Based Digital Spatial Profiling of Benign Breast Lobules and Breast Cancers: Feasibility, Biological Coherence, and Cross-Platform Benchmarks","","Discovering reliable risk biomarkers from scarce benign breast disease biopsies is limited by tissue availability and microanatomic heterogeneity. A pilot assessed whether tissue-sparing tissue microarray (TMA)-based digital spatial profiling (DSP) yields reproducible, biologically coherent protein measurements across benign lobules and breast cancers, and how DSP matches standard immunoassays. DSP quantified 79 proteins (37 after QC) and benchmarked results against IHC and OPAL immunofluorescence. Reproducibility and cross-platform agreement were evaluated using ICCs, weighted kappa, correlations, and mixed-effects models with FDR control.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tissue-microarray-based-digital-spatial-profiling-of-benign-breast-lobules-and-breast-cancers-feasibility-biological-coherence-and-cross-platform-benchmarks/368972/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tissue-microarray-based-digital-spatial-profiling-of-benign-breast-lobules-and-breast-cancers-feasibility-biological-coherence-and-cross-platform-benchmarks/368972.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-22","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study?","Question",{"text":112,"@type":113},"To test whether TMA-based digital spatial profiling can reproducibly measure proteins across benign breast lobules, breast cancers, and related tissue, while remaining biologically coherent and consistent with standard immunoassays.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was digital spatial profiling benchmarked against standard tests?",{"text":117,"@type":113},"DSP protein measurements were compared with chromogenic IHC and OPAL immunofluorescence using reproducibility metrics and cross-platform agreement methods.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about performance across tissue contexts?",{"text":121,"@type":113},"Agreement and reproducibility were highest in breast cancer tissues, while terminal duct lobular units showed lower consistency; exploratory differences in benign lobule contexts did not persist after FDR control.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368972,1790899124,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Article  \nTissue Microarray-Based Digital Spatial Profiling of Benign Breast Lobules and Breast Cancers: Feasibility, Biological Coherence, and Cross-Platform Benchmarks  \nMark E. Sherman 1, Jodi C. Carter 2, Robert A. Vierkant 3, Melody Stallings-Mann 4, Laura Pacheco-Spann 1, Stacey J. Winham 3, Celine M. Vachon 5, Chen Wang 3, Matthew R. Jensen 3, Melissa A. Troester 6,7, Amy C. Degnim 8, E. Aubrey Thompson 4, Jennifer Kachergus 4, Ji Shi 4 and Derek C. Radisky 4, *  \nAcademic Editors: Cristian Scatena and Carmine De Angelis  \nReceived: 3 November 2025  \nRevised: 19 November 2025  \nAccepted: 21 November 2025  \nPublished: 27 November 2025  \nCitation: Sherman, M.E.; Carter, J.C.; Vierkant, R.A.; Stallings-Mann, M.; Pacheco-Spann, L.; Winham, S.J.; Vachon, C.M.; Wang, C.; Jensen, M.R.; Troester, M.A.; et al. Tissue Microarray-Based Digital Spatial Profiling of Benign Breast Lobules and Breast Cancers: Feasibility, Biological Coherence, and Cross-Platform Benchmarks. Cancers 2025, 17, 3797 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers17233797  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Quantitative Health Sciences, Mayo Clinic Alix School of Medicine and Health Sciences, Jacksonville, FL 32225, USA; [pachecospann.laura@mayo.edu](pachecospann.laura@mayo.edu) (L.P.-S.)  \n2 Department of Laboratory Medicine and Pathology, University of Alberta, 114 Street and 89 Avenue, Edmonton, AB T6G 2M7, Canada  \n3 Quantitative Health Sciences, Mayo Clinic Alix School of Medicine and Health Sciences, Rochester, MN 55905, USA  \n4 Cancer Biology, Mayo Clinic, Jacksonville, FL 32225, USA  \n5 Division of Epidemiology, Mayo Clinic Alix School of Medicine and Health Sciences, Rochester, MN 55905, USA  \n6 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA  \n7 Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA  \n8 Department of Surgery, Mayo Clinic Alix School of Medicine and Health Sciences, Rochester, MN 55905, USA  \n* Correspondence: [radisky.derek@mayo.edu](radisky.derek@mayo.edu)  \nSimple Summary  \nMost breast biopsies show non-cancerous (benign) changes, yet some women later develop breast cancer. Predicting who is at higher risk from these small tissue samples is difficult because the relevant structures are tiny and easily exhausted by testing. We evaluated whether a multiplex technology called digital spatial profiling can measure many proteins at once on tissue microarrays built from benign breast lobules, nearby tissue next to cancers, and cancers themselves. We also compared the results to standard lab tests. The approach worked well overall and reproduced known biology, especially in cancer tissue. Signals in benign lobules were more variable and did not, on their own, distinguish women who later developed cancer from matched controls in this pilot. These findings show that high-plex, tissue-conserving profiling is feasible and biologically coherent, and they outline concrete ways to improve sampling and marker panels for future risk-prediction studies.  \nAbstract  \nBackground: Discovering risk biomarkers in small benign breast disease (BBD) biopsies is constrained by scarce tissue and microanatomic heterogeneity of terminal duct lobular units (TDLUs) . We tested whether tissue-sparing tissue microarray (TMA)–based Digital Spatial Profiling (DSP) can deliver reproducible, biologically coherent protein measurements across benign lobules and breast cancers (BCs), and how well DSP aligns with standard immunoassays. Methods: We performed a pilot using tissues from the Mayo Cli","cbCaiddR8aUi0ncL","https://ap.wps.com/l/cbCaiddR8aUi0ncL","pdf",953351,17,"English","# Introduction\n# Simple Summary\n# Abstract\n# Keywords","[{\"question\":\"What is the main goal of the study?\",\"answer\":\"To test whether TMA-based digital spatial profiling can reproducibly measure proteins across benign breast lobules, breast cancers, and related tissue, while remaining biologically coherent and consistent with standard immunoassays.\"},{\"question\":\"How was digital spatial profiling benchmarked against standard tests?\",\"answer\":\"DSP protein measurements were compared with chromogenic IHC and OPAL immunofluorescence using reproducibility metrics and cross-platform agreement methods.\"},{\"question\":\"What did the study find about performance across tissue contexts?\",\"answer\":\"Agreement and reproducibility were highest in breast cancer tissues, while terminal duct lobular units showed lower consistency; exploratory differences in benign lobule contexts did not persist after FDR control.\"}]","Tissue Microarray-Based Digital Spatial Profiling of Benign Breast Lobules and Breast Cancers: Feasibility, Biological Coherence, and Cross-Platform Benchmarks | PDF",1790179978,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/056d419dfded4bf998d919f79bccdcfc.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23856bb01af2a1384916cb2560910b7a.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88732b44837faa9d1b82b5e6a7afe7af.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4179633de7efa01b51bc90612a6364cc.webp",980,1385]